Chordate Medical receives its first installation of the Ozilia migraine treatment at a private clinic in Hamburg

Chordate Medical has secured an agreement for the immediate installation of equipment and consumables for the Ozilia treatment for chronic migraines. The agreement was reached through the company’s marketing consultants in Germany. The customer is a private specialist clinic in Hamburg.

“It is very satisfying to achieve a breakthrough in Germany as it is one of the markets we are focusing on. This will undoubtedly make it easier to continue converting prospects into orders in Germany. The agreement came about thanks to the skilled work of our German market experts,” says Anders Weilandt, CEO of Chordate.



Chronic migraines in Germany
Migraine is one of the most common diseases globally, with approximately 12.5 million people in Germany suffering from migraines in some form. That’s about one in seven Germans. Globally, it affects around 1.2 billion people. Between 1.5 and 1.8 million Germans have chronic migraines. Migraine and headache care in the country are among the most advanced in Europe, and the market for migraine medications is one of the largest in the world. These conditions where part of the reason why Chordate conducted its recently concluded clinical study in Germany.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy